The induction of CD8+ T-cell-mediated immunity against antigens released from normal melanocytes is exploited to destroy metastatic melanomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ribas, A., Butterfield, L.H., Glaspy, J.A. & Economou, J.S. J. Clin. Oncol. 21, 2415–2432 (2003).
Campoli, M. & Ferrone, S. Expert Rev. Vaccines 3, 171–187 (2004).
Daniels, G.A. et al. Nat. Biotechnol. 22, 1125–1132 (2004).
Renkvist, N., Castelli, C., Robbins, P.F. & Parmiani, G. Cancer Immunol. Immunother. 50, 3–15 (2001).
Gilboa, E. Immunity 11, 263–270 (1999).
Luo, W. et al. Cancer Chemother. Biol. Resp. Modif. In press (2004).
Ferrone, S. & Marincola, F.M. (eds.). Semin. Cancer Biol. 13, 387–480 (2003).
Harris, M. Lancet Oncol. 5, 292–302 (2004).
den Brok, M.H. et al. Cancer Res. 64, 4024–4029 (2004).
French, R.R., Chan, H.T., Tutt, A.L. & Glennie, M.J. Nat. Med. 5, 548–553 (1999).
Melero, I. et al. Nat. Med. 3, 682–685 (1997).
Leach, D.R., Krummel, M.F. & Allison, J.P. Science 271, 1734–1736 (1996).
Marincola, F.M., Jaffee, E.M., Hicklin, D.J. & Ferrone, S. Adv. Immunol. 74, 181–273 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ferrone, S. Immunotherapy dispenses with tumor antigens. Nat Biotechnol 22, 1096–1098 (2004). https://doi.org/10.1038/nbt0904-1096
Issue Date:
DOI: https://doi.org/10.1038/nbt0904-1096
This article is cited by
-
The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site
Molecular Therapy (2014)
-
Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse
Molecular Therapy (2013)
-
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
Nature Biotechnology (2012)
-
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
Nature Medicine (2011)
-
TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines
Cancer Immunology, Immunotherapy (2007)